Betta Pharmaceuticals Co., Ltd. (300558.SZ) Latest Company News

Oct 28, 2026, 11:16 UTC
Beda Pharmaceutical’s board approved a related-party technology transfer agreement with Hangzhou Shengsi Biotech for rights to the SS202 long-acting growth hormone project, with RMB 40 million in milestone payments, including an RMB 10 million upfront payment, plus royalties after commercialization.
Source:
- finance.sina.cn
Oct 26, 2026, 11:43 UTC
Beda Pharmaceutical said its concerted actor Kaiming Investment added a supplementary pledge of 450,000 shares and extended the repurchase date for 2.75 million previously pledged shares, with no new financing involved.
Source:
- finance.sina.cn
Oct 20, 2026, 11:20 UTC
China's National Medical Products Administration accepted Betta Pharmaceuticals' clinical trial application for injectable BPI-585771, intended to treat advanced solid tumors.
Source:
- finance.sina.cn
Oct 20, 2026, 11:13 UTC
China’s National Medical Products Administration accepted BeiGene’s clinical trial application for injectable BPI-585771, intended to treat advanced solid tumors.
Source:
- finance.sina.cn
Oct 19, 2026, 12:52 UTC
EyePoint, Inc. reported that the LUCIA Phase III trial of DURAVYU for wet age-related macular degeneration missed its primary endpoint, while key secondary endpoints were met; at week 56, 52% of participants needed no supplemental treatment and 71% needed zero or one supplemental treatment.
Source:
- finance.sina.cn
Oct 16, 2026, 08:06 UTC
China’s National Medical Products Administration accepted five clinical-trial applications for Jingyao Biotech’s BPI-57.23 capsules in combination regimens, with three acceptance numbers listed.
Source:
- finance.sina.cn
Sep 3, 2026, 07:51 UTC
Betta Pharmaceuticals announced that China's National Medical Products Administration issued a drug registration certificate for ensartinib capsules (brand name: Benmeina), approving a new indication for adjuvant treatment of ALK-positive stage IB to IIIB non-small cell lung cancer after surgery, the third approved indication for ensartinib.
Source:
- finance.sina.cn
Aug 21, 2026, 15:43 UTC
Betta Pharmaceuticals held a conference call on August 21, 2026 to discuss its 2026 half-year results, reporting revenue of 1.976 billion yuan, up 14% year-on-year.
Source:
- wap.eastmoney.com
Aug 18, 2026, 03:34 UTC
On August 18, 2026, Betta Pharmaceuticals' shares plunged 20% to the daily limit in early trading, following a sharp decline in the US stock EyePoint Pharmaceuticals after its Phase III trial failed to meet the primary endpoint.
Source:
- finance.ifeng.com
Aug 10, 2026, 11:06 UTC
Shareholder Hangzhou Teruixichuang Enterprise Management Partnership reduced 495,900 shares of Betta Pharmaceuticals through centralized bidding trading from May 8 to August 7, 2026, accounting for 0.1171% of total share capital at an average price of 69.99 yuan per share, and the reduction plan period has expired.
Source:
- finance.sina.cn
Jul 17, 2026, 07:50 UTC
Betta Pharma received approval from the National Medical Products Administration for a clinical trial of Icotinib Hydrochloride Tablets (Conmana) for postoperative adjuvant treatment of IA2 high-risk to stage IB EGFR-mutant non-small cell lung cancer.
Source:
- finance.sina.cn
Jul 10, 2026, 10:35 UTC
China's National Health Commission and multiple departments published the 2026 edition of the National Essential Drugs List, which includes three drugs from Betta Pharma: bevacizumab (newly added), icotinib, and trastuzumab (both continued from the 2018 edition).
Source:
- finance.sina.cn
Jul 9, 2026, 00:15 UTC
Betta Pharma's clinical study on ensartinib (Bemena) as adjuvant therapy for ALK-positive NSCLC was published online in the New England Journal of Medicine.
Source:
- finance.sina.cn

300558.SZ

Beda Pharmaceutical said its concerted actor Kaiming Investment added a supplementary pledge of 450,000 shares and extended the repurchase date for 2.75 million previously pledged shares, with no new financing involved.

China's National Medical Products Administration accepted Betta Pharmaceuticals' clinical trial application for injectable BPI-585771, intended to treat advanced solid tumors.

China’s National Medical Products Administration accepted BeiGene’s clinical trial application for injectable BPI-585771, intended to treat advanced solid tumors.

EyePoint, Inc. reported that the LUCIA Phase III trial of DURAVYU for wet age-related macular degeneration missed its primary endpoint, while key secondary endpoints were met; at week 56, 52% of participants needed no supplemental treatment and 71% needed zero or one supplemental treatment.

China’s National Medical Products Administration accepted five clinical-trial applications for Jingyao Biotech’s BPI-57.23 capsules in combination regimens, with three acceptance numbers listed.

Betta Pharmaceuticals held a conference call on August 21, 2026 to discuss its 2026 half-year results, reporting revenue of 1.976 billion yuan, up 14% year-on-year.

On August 18, 2026, Betta Pharmaceuticals' shares plunged 20% to the daily limit in early trading, following a sharp decline in the US stock EyePoint Pharmaceuticals after its Phase III trial failed to meet the primary endpoint.

Betta Pharma received approval from the National Medical Products Administration for a clinical trial of Icotinib Hydrochloride Tablets (Conmana) for postoperative adjuvant treatment of IA2 high-risk to stage IB EGFR-mutant non-small cell lung cancer.

China's National Health Commission and multiple departments published the 2026 edition of the National Essential Drugs List, which includes three drugs from Betta Pharma: bevacizumab (newly added), icotinib, and trastuzumab (both continued from the 2018 edition).

Betta Pharma's clinical study on ensartinib (Bemena) as adjuvant therapy for ALK-positive NSCLC was published online in the New England Journal of Medicine.